MS-553
Phase 1/2- Indications
- Chronic lymphocytic leukemia, Small lymphocytic lymphoma, Diabetic macular edema, Diabetic retinopathy
Company intelligence / Profile preview
Jiangsu MingSight-Relin Pharmaceutical
Jiangsu, Chinamingsight.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Jiangsu MingSight–Relin Pharmaceutical was established as a joint venture between Shenzhen Relin Medicine and MingSight Pharmaceuticals to develop and commercialize MS‑553—a selective oral PKCβ inhibitor—for diabetic eye disease in China. The company has also advanced MS‑553 into clinical trials for hematologic cancers such as CLL/SLL. As of April 2025, the company reinitiated a phase I trial in diabetic macular edema after previous suspensions due to protocol revisions. A phase I/II trial in CLL/NHL was terminated due to major protocol changes. Proof-of-concept data have been reported for both oncology and ophthalmology indications.
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Partnership between Shenzhen Relin Medicine and MingSight Pharmaceuticalsoriginal compound licensed from Pfizer
Beyond the preview
Go deeper on Jiangsu MingSight-Relin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu MingSight-Relin Pharmaceutical.